Skip to content Carb-X
Carb-X
Boston University
Mobile Menu Toggle navigation
  • Contact
  • Twitter
  • LinkedIn
Carb-X
Boston University
Boston University
  • About CARB-X
    • Overview
    • Global Threat
    • Our Strategy
    • Stewardship and Access
    • Management & Staff
    • Joint Oversight Committee
    • Advisory Board
    • Careers
    • Annual Reports
    • Boston University
  • Portfolio
    • Portfolio-Product Developers
    • Portfolio-Pipeline
    • CARB-X Graduates
    • Spotlight on Science
    • Portfolio Acceleration Tools
  • Partners
    • Funding Partners
    • Global Accelerator Network
  • Apply
    • Application Process
    • The CARB-X Process
    • Official Development Assistance
    • Research Compliance
    • Additional Information and Resources
    • Apply Here
  • Resources
    • Presentations
    • Videos
    • Publications
    • Education
    • PD Resources
  • News
    • CARB-X News
    • In the News
    • Antibiotic Resistance
    • Media Resources
  • Events
  • About CARB-X
    • Overview
    • Global Threat
    • Our Strategy
    • Stewardship and Access
    • Management & Staff
    • Joint Oversight Committee
    • Advisory Board
    • Careers
    • Annual Reports
    • Boston University
  • Portfolio
    • Portfolio-Product Developers
    • CARB-X Graduates
    • Spotlight on Science
  • Partners
    • Funding Partners
    • Global Accelerator Network
  • Apply
    • Application Process
    • The CARB-X Process
    • Official Development Assistance
    • Research Compliance
    • Additional Information and Resources
    • Apply Here
  • Resources
    • Presentations
    • Videos
    • Publications
    • Education
    • PD Resources
  • News
    • CARB-X News
    • In the News
    • Antibiotic Resistance
    • Media Resources
  • Events
  • Contact
  • Legal

Portfolio Company

  • Portfolio
  • >
  • Gallery
Eligo Bioscience

Eligo Bioscience, Paris, France
https://eligo.bio/

EB004 – PHAGE-CRISPR
NON-TRADITIONAL BACTERIOPHAGE

Prevention of MDR infections in Microbiome

Eligo is developing an innovative CRISPR-based bacteriophage therapeutic that aims to specifically kill antibiotic-resistant bacteria before an infection has a chance to occur in the gut of organ-transplant patients. The goal is to significantly reduce the risk of antibiotic treatment failures (and subsequent deaths). Eligo’s technology transforms bacteriophages into safe, non-replicative DNA-delivery vectors. The vectors are programmed to inject a synthetic DNA payload directly into the target bacterial populations of the patient’s gastrointestinal tract. The DNA payload is optimized to circumvent bacterial defense mechanisms and enables the expression of a CRISPR-Cas system that creates double strand DNA breaks only in antibiotic resistance genes carried by the targeted bacteria. This mechanism leads to the selective killing of bacteria carrying these genes, while a patient’s bacteria that do not carry these genes are left unharmed. If successful, the EB004 program could pave the way for personalized decolonization treatments to improve patient care, antibiotic stewardship, and patient prognosis, without disrupting the patient’s beneficial microbiota.

Current Development Stage: Hit-to-lead

CARB-X Investment: Initial investment of up to $1.82m with potential option payments up to $5.23m.

Initial CARB-X Investment Date: April 1, 2020

Carb-X

Led by Boston University

Copyright 2022

  • Contact
  • Careers
  • Site Credits
  • Legal
  • Twitter
  • LinkedIn

Copyright 2022